Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00466063 · ClinicalTrials.gov registry record
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 108
- Enrollment target
NCT00466063: Completed study, sponsored by Novartis Pharmaceuticals.
NCT00466063 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 108 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00466063 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 108 participants
- Enrollment target
Study Summary
This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.
Interventions
- DRUG Deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2007-05 |
| Est. Completion | 2015-07 |
What the finished NCT00466063 record still lists
NCT00466063 is an observational study that tracks outcomes without assigning an intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Deferasirox is the first listed.
NCT00466063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00466063 about?
NCT00466063 is a clinical study titled "ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox". This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.
What is the current status of trial NCT00466063?
This trial is currently completed. The enrollment target is 108 participants. The study started on 2007-05. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00466063?
The interventions under investigation include: Deferasirox (DRUG).
Who is sponsoring clinical trial NCT00466063?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia